MedTrace Logo

Improving Health Literacy in African-American Prostate Cancer Patients

NCT03322891 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 210

Last updated 2026-01-29

No results posted yet for this study

Summary

Investigators propose an observational interview study to explore how patients understand treatment conversations with their physicians within the framework of health literacy. The study team will test whether patients' understanding of treatment options and side effects can be improved when patients receive a low literacy educational supplement after meeting with their urologist. Investigators will interview a group of newly diagnosed, early stage, African American prostate cancer patients.

Conditions

Interventions

OTHER

Educational Supplement

Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.

OTHER

Standard Practice Education

Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Emory University

    lead OTHER

Principal Investigators

  • Kerry Kilbridge, MD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
25 Years
Max Age
100 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-21
Primary Completion
2027-03-31
Completion
2027-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03322891 on ClinicalTrials.gov